Recent advances in adjunctive therapy for epilepsy: Focus on sodium channel blockers as third-generation antiepileptic drugs

Drugs of Today

Volumn 46, Issue 4, 2010, Pages 265-277

  Vohora, Divya ^a   Saraogi, P ^a   Yazdani, M A ^a   Bhowmik, M ^a   Khanam, R ^a   Pillai, K K ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BRIVARACETAM; CARBAMAZEPINE; CARBAMIC ACID 2 (2 CHLOROPHENYL) 2 HYDROXYETHYL ESTER; CARISBAMATE; CLOBAZAM; DIAZEPAM; DIGOXIN; ELPETRIGINE; ESLICARBAZEPINE ACETATE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FLUOROFELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; RUFINAMIDE; SAFINAMIDE; SODIUM CHANNEL BLOCKING AGENT; TOLBUTAMIDE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VINPOCETINE; WARFARIN; ZONISAMIDE;

ABSENCE OF SIDE EFFECTS; ACNE; ANHIDROSIS; ANOREXIA; ANTIOXIDANT ACTIVITY; APLASTIC ANEMIA; ATAXIA; BEHAVIOR CHANGE; BICARBONATE BLOOD LEVEL; BLURRED VISION; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COMPLEX III DEFICIENCY; DEPRESSION; DIPLOPIA; DIZZINESS; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EPILEPSY; EPILEPTIC STATE; FATIGUE; FIBROMYALGIA; FLUSHING; FOCAL EPILEPSY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GENERALIZED EPILEPSY; GRAND MAL SEIZURE; HUMAN; HYPONATREMIA; HYPOTENSION; INSOMNIA; IRRITABILITY; LENNOX GASTAUT SYNDROME; LIVER TOXICITY; LYMPHADENOPATHY; MANIA; MENTAL DISEASE; MIGRAINE; MOOD DISORDER; NAUSEA; NEPHROLITHIASIS; NEUROPATHIC PAIN; NEUROPROTECTION; NIGHTMARE; NONHUMAN; NYSTAGMUS; PAIN; PARESTHESIA; PARKINSONISM; PARTIAL ONSET SEIZURE; PHOTOSENSITIVE EPILEPSY; PR INTERVAL; PRURITUS; REVIEW; RHINOPHARYNGITIS; SEIZURE; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TERATOGENICITY; THROMBOCYTE COUNT; TONIC CLONIC SEIZURE; TOOTH DISEASE; TOXIC EPIDERMAL NECROLYSIS; TREMOR; VERTIGO; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ANIMALS; ANTICONVULSANTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG INTERACTIONS; EPILEPSY; HUMANS; SODIUM CHANNEL BLOCKERS;

EID: 77954421654     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.4.1445795     Document Type: Review

References (64)

1. www.who.int/mediacenter/factsheets
2. Bialer, M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs 2006, 15(6): 637-47.
3. Stefan, H., Feurstein, T.J. Novel anticonvulsant drugs. Pharmac Ther 2007, 113(1): 165-83.
4. Kwan, P., Brodie, M.J. Refractory epilepsy: mechanism and solution. Expert Rev Neurothera 2006, 6(3): 397-406.
5. Pellock, J.M., Watemberg, N. New antiepileptic drugs in children: present and children. Semin Pediatr Neurol 1997, 4(1): 9-18. (Pubitemid 27137470)
6. Luszcki, J.J. Third generation antiepileptic drugs: mechanism of action, pharmacokinetics and interactions. Pharmac Rep 2009, 61(2): 197-16.
7. Perucca, E. Established antiepileptic drugs. Baillieres Clin Neurol 1996, 5(4): 693-22.
8. Herman, S.T., Pedley, T.A. New options for the treatment of epilepsy. JAMA 1998, 280(8): 693-4.
9. Rogawski, M.A. Brivaracetam: A rational drug discovery success story. Br J Pharmacol 2008, 154(8): 1555-7.
10. Rogawski, M.A. New molecular targets for antiepileptic drugs: a2d, SV2A and Kv7/ KCNQ/ M potassium channels. Curr Neurol Neurosci Rep 2008, 8(4): 345-52.
11. + channel-mediated release. Neuropharmacology 2007, 53(7): 854-862.
12. Bialer, M., Johannessen, S.I., Kupferberg, H.J., Levy, R.H., Perucca, E., Tomson, T., SteveWhite, H. Progress report on new antiepileptic drugs: A summary of the Ninth EILAT Conference (EILAT IX). Epilepsy Res 2009, 83(1): 1-43.
13. Rogawski, M.A. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 2006, 69(3): 273-94.
14. Clare, J.J., Tate, S.N., Nobbs, M., Romanos, M.A. Voltage-gated sodium channels as therapeutic targets. Drug Discov Today 2000, 5(11): 506-20.
15. Shao, D., Okuse, K., Djamgoz, M.B.A. Protein-protein interactions involving voltage-gated sodium channels: Post-translational regulation, intracellular trafficking and functional expression. Int J Biochem Cell Biol 2009, 41(7): 1471-81.
16. Ragsdale, D.S., Avoli, M. Sodium channels as molecular targets for antiepileptic drugs. Brain Res Rev 1998, 26(1): 16-28. (Pubitemid 28179007)
17. Bolcskei, H., Tarnawa, I., Kocsis, P. Voltage gated sodium channel blockers.2001-2006: An overview. Med Chem Res 2008, 17: 356-368.
18. Tarnawa, I., Bolcskei, H., Kocsis, P. Blockers of voltage gated sodium channels for the treatment of CNS diseases. Recent Pat CNS Drug Discov 2007, 2(1): 57-78.
19. Beyreuther, B.K., Freitag, J., Heers, C., Krebsfanger, N., Scharfeneckar, U., Stohr, T. Lacosamide: A review of preclinical properties. CNS Drug Rev 2007, 13(1): 21-42.
20. Wehner, T., Bauer, S., Hamer, H.M. et al. Six months of post marketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany. Epilepsy Behav 2009, 16(3): 423-5.
21. Errington, A.C., Coyne,L., Stöhr, L., Selve, N., Lees, G. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 2006, 50(8): 1016-29.
22. Kellinghaus, C. Lacosamide as treatment for partial epilepsy: mechanism of action, pharmacology, effects and safety. Ther Clin Risk Manag 2009, 5: 757-66.
23. McCormack, P.L., Robinson, D.M. Eslicarbazepine acetate. CNS Drugs 2009, 23(1): 71-9.
24. Ambrosio A.F., Silva, A.P., Malva, J.O., Soares-da-Silva, P., Carvalho, A.P., Carvalho, C.M. Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels. Biochem Pharmacol 2001, 61(10): 1271-5.
25. Almeida, L., Soares-da-Silva, P. Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics 2007, 4(1): 88-96.
26. Roecklein, B.A., Sacks, H.J., Mortko, H., Stables, J. Fluorofelbamate. Neurotherapeutics 2007, 4(1): 97-101.
27. Bialer, M., Johannessen, S.I., Kupferberg, H.J., Levy, R.H., Perucca, E., Tomson, T. Progress report on new antiepileptic drugs: A summary of the Seventh EILAT Conference (EILAT VII). Epilepsy Res 2004, 61(1-3): 1-48. (Pubitemid 39296697)
28. Liu, Y., Yohrling, J.G., Wang, Y., Hutchinson, T.L., Brenneman, D.E., Flores, C.M., Zhao, B. Carisbamate, a novel neuromodulator, inhibits voltage gated sodium channels and action potential firing of rat hippocampal neurons. Epilepsy Res 2009, 83(1): 66-72.
29. Arroyo, S. Rufinamide. Neurotherapeutics 2007, 4(1): 155-62.
30. Kluger, G., Kurlemann, G., Haberlandt, E. et al. Effectiveness and tolerability of rufnamide in children and adults with refractory epilepsy: First European experience. Epilepsy Behav 2009, 14(3): 491-5.
31. Marzo, A., Dal Bo, L., Monti, N.C. et al. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res 2004, 50(1): 77-85.
32. Bonoczk, P., Gulyas, B., Adam-Vizi, V. et al. Role of sodium channel inhibition in neuroprotection: Effect of vinpocetine. Brain Res Bull 2000, 53(3): 245-54.
33. Miyamoto, M., Murphy, T.H., Schnaar, R.L., Coyle, J.T. Antioxidants protect against glutamate induced cytotoxicity in a neuronal cell line. J Pharmacol Exp Ther 1989, 250(3): 1132-40. (Pubitemid 19246731)
34. Nyakas, C., Felszeghy, K., Szabó, R., Keijser, J. N., Luiten, P. G., Szombathelyi, Z., Tihanyi, K. Neuroprotective effects of vinpocetine and its major metabolite cis-apovincaminic acid on NMDA-induced neurotoxicity in a rat entorhinal cortex lesion model. CNS Neurosci Ther 2009, 15(2): 89-99.
35. Dutov, A.A., Tolpyshev, B.A., Karpov, V.N., Petrov, A.P. Effect of Cavinton on convulsions caused by chemical substances. Farmakol Toksikol 1986, 49(4): 22-5.
36. Vas, A., Gulyás, B. Eburnamine derivatives and the brain. Med Res Rev 2005, 25(6): 737-57.
37. 2+ and glutamate release in hippocampal isolated nerve endings. Neurochem Int 2006, 49(1): 55-61.
38. Von Rosenstiel, P. Brivaracetam (UCB-34714). Neurotherapeutics 2007, 4(1): 84-7.
39. Novak, G.P., Kelly, M., Zannikos, P., Klein, B. Carisbamate (RWJ-333369). Neurotherapeutics 2007, 4(1): 106-109.
40. Nehlig, A., Rigoulot, M.A., Boehrer, A. A new drug, RWJ-333369, displays potent antiepileptic properties in genetic models of absence and audiogenic epilepsy. Epilepsia 2005, 46(Suppl. 8): Abst 2638.
41. Grabenstatter, H.L., Dudek, F.E. A new potential AED, carisbamate, substantially reduces spontaneous motor seizures in rats with kainate-induced epilepsy. Epilepsia 2008, 49(10): 1787-94.
42. Matagne, A., Margineanu, D.G., Kenda, B., Michel, P., Klitgaard, H. Anticonvulsive and antiepileptic properties of brivaracetam (UCB 34714), a high affinity synaptic vesicle protein SV2A ligand. Br J Pharmacol 2008, 154(8): 1662-71.
43. Mazarati, A.M., Sofia, R.D., Wasterlain, C.G. Anticonvulsant and antiepileptogenic effects of fluorofelbamate in experimental status epilepticus. Seizure 2002, 11(7): 423-30.
44. Bialer, M., Johannessen, S.I., Kupferberg, H.J., Levy, R.H., Perucca, E., Tomson, T. Progress report on new antiepileptic drugs: A summary of the Eight EILAT Conference (EILAT VIII). Epilepsy Res 2007, 73(1): 1-52.
45. Fariello, R.G. Safinamide. Neurotherapeutics 2007, 4(1): 110-6.
46. Doty, P., Rudd, G.D., Stoehr, T., Thomas, D. Lacosamide. Neurotherapeutics: 2007, 4(1): 145-8.
47. Nekrassov, V., Sitges, M. Comparison of acute, chronic and post-treatment effects of carbamazepine and vinpocetine on hearing loss and seizures induced by 4-aminopyridine. Clin Neurophysiol 2008, 119(11): 2608-14.
48. White, H.S., Schmutz, M., Pozza, M., Wolf, H., Stables, J., Kupferberg, H. The anticonvulsant profile and tolerability of rufinamide in mice and rats. Epilepsia 2005, 46(Suppl. 8): Abst 3088.
49. Bhatti, J.Z., Hindmarch, I. Vinpocetine effects on cognitive impairments produced by flunitrazepam. Int Clin Psychopharmacol 1987, 2(4): 325-31.
50. Pereira, C., Agostinho, P., Moreira, P.I., Duarte, A.I., Santos, M.S., Oliveira, C.R. Neuroprotection strategies: effect of vinpocetine in vitro oxidative stress models. Acta Med Port 2003, 16(6): 401-6.
51. Foreman, M.M., Hanania, T., Stratton, S.C., Wilcox, K.S., Steve White, H., Stables, J.P., Eller, M. In vivo pharmacological effects of elpetrigine, a novel anticonvulsant, in models for anticonvulsant, antimania and antidepressant activity. Pharmacol Biochem Behav 2008, 89(4): 523-34.
52. Nagel, A. G., Lopes-lima, J., Almeida, L., Soares-da-silva, P. Efficacy and safety of 800 and 1200 mg Eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures. Acta Neurol Scand 2009, 120(5): 281-7.
53. Almeida, L., Falcao, A., Maia, J., Mazur, D., Gellert, M., Soares-da-Silva, P. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol 2005, 45(9): 1062-66.
54. Vaz da Silva, M., Costa, R., Soares, E., Maia, J., Falcao, A., Almeida, L., Soares da Silva, P. Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects. Fundam Clin Pharmacol 2009, 23(4): 509-14.
55. Sargentini-Maier, M.L., Espié, P., Coquette, A., Stockis, A. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos 2008, 36(1): 36-45.
56. Rolan, P., Sargentini-Maler, M.L., Plgeolet, E., Stockls, A. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol 2008, 66(1): 71-5.
57. Mannes, G.S., Hendrick, J., Janssen, C.G. et al. The absorption, metabolism and excretion of the novel neuromodulator RWJ-333369 in humans. Drug Metab Dispos 2007, 35(4): 554-65.
58. Chien, S., Bialer, M., Solanki, B. Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy subjects. Epilepsia 2006, 47(11): 1830-9.
59. th World Congr Pain (Aug 21-26, Sydney) 2009, Abst 602-P208.
60. Lohmann, A., Dingler, E., Sommer, W., Schaffler, K., Wober, W., Schmidt, W. Bioavailability of vinpocetine and interference of the time of application with food intake. Arzneimittelforschung 1992, 42(7): 914-7.
61. Vinpocetine. Altern Med Rev 2002, 7(3): 240-3.
62. Martinez, W., Ingenito, A., Blakeslee, M., Barkley, G. L., McCague, K., D'Souza, J. Efficacy, safety and tolerability of oxcarbazepine monotherapy. Epilepsy Behav 2006, 9(3): 448-56.
63. Kwan, P., Sills, G.J., Brodie, M.J. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol Ther 2001, 90(1): 21-34.
64. Perucca, E. A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol Res 1997, 35(4): 241-56.